ArticleLung2024

Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).

Nobuhiro Kanaji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.